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Design, formulation and sensory evaluation of a polyphenol-rich food
placebo: an example of aronia juice for food intervention studies
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ABSTRACT
Products suitable for use as controls in food interventions designed to demonstrate the role of
minor components are largely lacking. In the present study, we aimed to develop a formulation
to be used as a placebo in a clinical trial designed to assess the effects of aronia juice polyphe-
nols on platelet function. Three formulations with the same nutrient composition as aronia juice
were prepared by mixing various nutrients, artificial colours and flavours with water. The similarity
of formulations to aronia juice in terms of taste, colour, smell and texture was assessed by six
food panellists. The final placebo was tested for its impact on platelet function, biochemical and
anthropometric parameters in a 4-week long study. No significant changes in platelet function, or
in several cardiovascular and safety markers were recorded. Formulation suitable for use as a pla-
cebo for dietary intervention studies using aronia juice has been developed and demonstrated to
be well tolerated in humans.
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Although placebo-controlled trials are essential for the
evaluation of successful interventions, products suit-
able for use as controls in food interventions designed
to demonstrate the role of minor components are
largely lacking. A placebo can be defined as an inter-
vention applied to mimic some other treatment in
most respects so that a comparison between the treat-
ment and placebo effectively identifies the different
components in the treatment as causing any observed
physiological effect. In drug trials, the most common
forms of placebos are capsules filled with an inert sub-
stance such as microcrystalline cellulose, but placebos
have been used for other kinds of interventions, even
physical interventions such as surgery (Vickers & de
Craen 2000). Although the main principles of pharma-
cological intervention trials should also be followed in
non-pharmacological interventions such as those with
foods, some concepts are difficult to apply in dietary
intervention studies (Yao et al. 2013). Ideally, placebo
formulations should be designed in a way to appear
largely indistinguishable from the tested materials
(appearance, smell, taste) but lack the specific compo-
nent(s) that putatively have biological activity
(de Craen et al. 1999). In the case of dietary
intervention studies, developing appropriate placebos
for the test foods is more challenging, particularly
when the compounds that contribute to the taste and
smell are at the same time the putatively active compo-
nents being assessed (Zick et al. 2005; Yoon et al.
2012). Example bioactive compounds include sulphur-
containing compounds present in cruciferous and
allium vegetables, highly coloured anthocyanins and
carotenoid pigments in various fruits and vegetables
and astringent proanthocyandins in apples and grape
skins. One of the most accurate approaches to achieve
a complex plant food placebo is to use plant genetic
modification (GM) to introduce or knockout the syn-
thesis of the bioactive components of interest. The use
of such an approach has been demonstrated with the
introduction of anthocyanin biosynthesis into tomatoes
which generated purple tomatoes that were rich in
anthocyanins and subsequently shown to extend the
lifespan of cancer-prone P57 knockout mice and reduce
the formation of atherosclerotic plaque in the ApoE
knockout mouse model (Butelli et al. 2008). However,
the acceptability of GM foods for human consumption
remains controversial, and current regulatory require-
ments ensure that such an approach is time consuming
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aronia (Aronia melanocarpa) has been of special inter-
est since its fruits have been indicated as a rich source
of polyphenols. Polyphenols from aronia fruits, mainly
anthocyanins and procyanidins, represent one of the
most potent natural antioxidants, exerting the positive
impact on overall health, but also on diseases and states
associated with marked level of oxidative stress, such as
cardiovascular diseases (CVD) and metabolic disorders
(Chrubasik et al. 2010; Sikora et al. 2014; Kardum et al.
2015). Although beneficial effects of aronia polyphenols
on CVD risk factors such as hypertension, elevated
blood lipids and glucose, platelet hyperactivity and
obesity have been demonstrated, controlled clinical tri-
als on aronia juice are still lacking, partly due to the
difficulties in delivering suitable control drink. In the
present work, we sought to develop and test a polyphe-
nol-free formulation that could be used as a placebo in
a clinical trial designed to assess the effects of the poly-
phenols in an aronia juice on platelet function and
other biomarkers and risk factors for CVD.
Material and methods
Development of placebo formulations
The aim of this study was to synthesise a formulation
that would have the same nutrient composition as
aronia juice, but that would lack bioactive polyphe-
nols. First we determined the composition of the
nutrients in aronia juice. We used a commercial juice,
prepared by Nutrika d.o.o. (Belgrade, Serbia), which
has been registered at the Serbian Ministry of Health
as a dietary supplement. The content of sugars was
measured by HPLC by previously described method
with slight modifications (Mikulic-Petkovsek et al.
2012), total acidity (expressed as citric acid) was deter-
mined by potentiometric titration, and minerals were
quantified using atomic absorption spectrometry, as
previously described (Vidovic et al. 2013). After the
chemical characterisation of aronia juice, we prepared
potential placebos using three different recipes con-
taining exactly the same content of sugars, citric acid,
vitamins and minerals as in the juice. The placebo for-
mulations were prepared by adding these nutrients to
water. All of the ingredients were safe and allowed for
human consumption and commonly used in the food
industry. Glucose and fructose were purchased from
LG Hemija (Serbia) and Barentz (the Netherlands),
respectively, while sorbitol and acidic acid were pur-
chased from Comcen (Serbia). Potassium, calcium and
magnesium were provided from LG Hemija (Serbia),
Applichem (USA) and Mitoku (Japan), respectively, in
the form of their corresponding salts. Sodium was
added from kitchen salt, and all of the vitamins were
obtained from Pharmanova (Serbia). Artificial colours
(“Bordeaux”, “Blue”, “Strawberry Red”, “Brilliant
Black”) and flavours (“Aronia” and “Blueberry”) were
used to mimic the appearance and taste of aronia
juice. They were supplied by “Frutarom Etol d.o.o.”
(Slovenia) and included components in accordance
with EC directives, in amounts permitted by the EU
legislation for liquid food supplements (Directive 94/
36/EC). The only differences between the three pla-
cebo formulations were the type and ratio of artificial
colours and flavours used for their preparation.
Sensory evaluation of placebo formulations
Sensory evaluation of placebo formulations was per-
formed by six independent food panellists. The panel-
lists were asked to compare the similarity of the three
placebo formulations to the aronia juice, which was
given first, at the start of the sensory testing. In order
to choose the best matching placebo, panellists were
served with three different formulations in random
order, in a single-blinded manner. An unsalted crack-
ers and water were offered in between.
First, panellists were asked to rate the degree of simi-
larity to aronia juice for the following parameters: taste,
colour, smell, texture and overall acceptability. For this
purpose the Likert category scale graded from 1 to 5
was used, with following meaning: 1¼ not at all, 2¼not
really, 3¼ undecided, 4¼ somewhat, 5¼ very much.
Afterwards, panellists graded the flavour of tested
liquids in terms of astringency, sourness and sweetness.
The degree of intensity for each attribute was assessed
with following scale: 0¼ not present, 1¼ just recognis-
able or threshold, 2¼weak, 3¼moderate, 4¼ strong,
5¼ very strong. Finally, a third scale was used to assess
the overall impression of matching the tested placebo
formulations with aronia juice by choosing one of the
following values: 1¼ low, 2¼medium, 3¼ high.
Testing of the final placebo formulation: pilot
study
The final placebo formulation was further tested in a
study population which included 20 healthy non-
diabetic volunteers (10 males, 10 females) aged 30–50
years. Subjects were pre-obese (body mass index:
25–30 kg/m2) with normal or high normal blood pres-
sure (systolic: 120–139mmHg) (Mansia et al. 2007)
and an increased waist circumference ( 80 cm for
females and 94 cm for men). The study had been
designed as open label, non-controlled with partici-











































































































2 N. KARDUM ET AL.
weeks (Ethical approval No 2125, Clinical Hospital
Zemun EB, 26th September 2013). The purpose of the
study was testing the possible impact of placebo con-
sumption on platelet function. Besides that, bio-
markers of liver and kidney function as additional
markers of placebo inertness were measured. Blood
samples were obtained at baseline and at the end of
the consumption period, after an overnight fast.
Additionally, anthropometric measurements, including
blood pressure level, were performed during both
study visits.
The aim of developing placebo beverage was its
application in a clinical trial assessing the effects of
the polyphenols in an aronia juice on platelet function
and other risk factors of CVD. In accordance with the
duration of intervention phases in this clinical trial,
we have chosen 4-week intervention period for our
pilot study. In addition, our previous research indi-
cated that 4-week interventions with Aronia juice
could express beneficial effects on blood pressure,
blood lipids, including fatty acid status, and pro-oxi-
dant/antioxidant status (Kardum et al. 2014a, 2015).
The beverage size in our pilot study was chosen in
accordance with the amount of aronia juice (100ml)
to be consumed in mentioned clinical trial testing
platelet function. This was rationalised by the amount
of total polyphenols, as active compounds of interest
and in accordance with amounts that have been
shown as effective in our previous research (Kardum
et al. 2014a, 2014b, 2015).
Sample collection and analyses
Venous blood was obtained after an overnight fast
and an initial 20-min rest. For the platelet analyses,
whole blood samples were collected into tubes with
sodium citrate as an anticoagulant, according to the
appropriate guidelines (Krueger et al. 2002).
Additional blood samples were collected into sample
tubes for serum in order to evaluate lipid status and
glucose level. The activity of liver enzymes and levels
of urea, creatinine and uric acid were determined
from the same samples. These analyses were per-
formed with a clinical chemistry analyser (Cobas c111,
Roche Diagnostics, Basel, Switzerland) and Roche’s
diagnostic kits according to the manufacturer’s
instructions
Flow cytometry/determination of platelet
activation and aggregation
The platelet activation markers (P-selectin and GPIIb-
IIIa) and platelet-leukocyte aggregates were measured
by whole-blood flow cytometry according to a previ-
ously published protocol (Michelson et al. 2000;
Krueger et al. 2002; Barnard et al. 2003). For the
determination of platelet activation, aliquots of whole
blood dissolved (1:10) in Hepes-Tyrode Buffer (HTB)
were incubated with peridinin chlorophyll protein
(PerCP)-conjugated anti-CD61, phycoerythrine (PE)-
conjugated CD62P (anti-P-selectin) and fluorescein
isothiocyanate (FITC)-conjugated PAC1 (anti-
GPIIb–IIIa) monoclonal antibodies with or without a
suboptimal concentration of platelet agonists (0.5lM
adenosine diphosphate, ADP) for 20min in the dark,
at room temperature. After the incubation with anti-
bodies, the samples were fixed in fixing buffer for
15min and analysed. Platelet-monocyte (PMA) and
platelet-neutrophil aggregates (PNA) were analysed
form whole blood samples, incubated with monoclonal
antibodies FITC-conjugated anti-CD61, PE-conjugated
anti-CD11b and PerCP-conjugated anti-CD14 with or
without suboptimal concentration of platelet agonist
(0.5lM ADP) for 15min in the dark, at room tem-
perature. Afterwards, samples were treated with
erythrocyte-lysing buffer for 10min, washed twice in
HTB, fixed for 15min in fixing buffer and analysed.
Sample analysis was performed using a FACS Calibur
flow cytometer with CellQuest software (Becton
Dickinson). The monoclonal antibodies, FACS Lysing
Solution and Cell Fix Solution were purchased from
Becton Dickinson (Heidelberg, Germany).
Statistical analysis
Prior to comparisons, the normality of variables distri-
bution was tested using the Shapiro–Wilk test.
Variables with normal distribution were compared by
paired samples t-test and data are shown as mean val-
ues ± standard deviation (SD). Non-parametric
Wilcoxon test was used for the comparisons of varia-
bles that were not normally distributed and these data
are presented as median and 25th–75th percentile. In
the case of platelet activation and aggregation markers,
data are shown graphically with Tukey “box and
whiskers” plots. On these plots, boxes present inter-
quartile range (IQR; the difference between the 25th
and 75th percentiles), horizontal lines are plotted at
the median, and vertical lines (whiskers) extend to the
largest and the smallest values. When there are out-
liers detected, defined as values differing more than
1.5 IQR from the 75th and the 25th percentiles, they
are presented as individual dots on graphs. In this
case, the upper whisker is drawn to the largest value
less than the sum of the 75th percentile and 1.5 IQR
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the 25th percentile minus 1.5 IQR. Analyses were per-
formed using the GraphPad Prism Software and
SPSS software (SPSS, Chicago, IL). p values <0.05
were used to indicate statistical significance.
Results
Placebo characterisation and sensory evaluation
The final polyphenol-free placebo beverage had the
same nutrient composition (i.e. content of sugars, cit-
ric acid, minerals and vitamins) as aronia juice. Along
with the aforementioned nutrients, artificial colours
(30mg of “Strawberry red” – SR and 10mg of
“Brilliant black” –BB/100ml) and artificial flavour
(100mg of “Blueberry” flavour/100ml) were added to
the water solution (Table 1). Since all the colouring
and flavouring agents were synthetic, no phenols were
present in the placebo formulation. The colours con-
sisted of dextrose and food additives. More precisely
SR was made of dextrose, sodium sulphate an food
additives: Ponceau 4R (E124), Sunset Yellow FCF
(E110), silicon dioxide (E551); while BB contained
dextrose, Brilliant Black BN (E151) and silicon dioxide
(E551).The flavour present in final placebo formula-
tion consisted of water, ethanol, Azorubine (E122)
and Brilliant Black BN (E151).
Characteristics of the subjects
General characteristics of the subjects who participated
in the pilot study are presented in Table 2. None of
the measured anthropometric parameters -including
blood pressure- and biochemical parameters was sig-
nificantly changed during the course of the study.
Effects on platelet activation and aggregation
In the case of platelet activation, there were no signifi-
cant changes observed in the expression of either of
the markers: P-selectin and GPIIbIIIa, both in basal
state or after responding to an agonist. Percentages of
antigen-positive platelets (from a platelet pool of
20,000 analysed cells) at baseline and after the 4 weeks
long consumption period are presented with box and
whisker plots in Figure 1. The formation of platelet-
leukocyte aggregates was evaluated by measuring the
expression of platelet-specific antigen CD61 in the
population of monocytes (assessed from a monocyte
pool of 1000 analysed cells) and neutrophils (assessed
from a neutrophil pool of 10,000 analysed cells). No
significant changes were found in the proportion of
platelet-monocyte and platelet-neutrophil aggregates,
either in basal state or after responding to an agonist.
The percentages of platelet-leukocyte aggregates at
baseline and at the end of the consumption period in
the basal state and after activation with ADP are pre-
sented at Figure 2.
Discussion
The present study indicates that, besides some limita-
tions in mimicking the astringent taste, each of the
sensory characteristics of aronia juice can be success-
fully matched to create a placebo beverage potentially
suitable for use in clinical trials to investigate the
physiological effects of consuming polyphenols in aro-
nia juice. All three placebo formulations were graded
with a weak presence of astringent taste, while overall
similarity to the aronia juice taste was evaluated with
a grade 2 (not really). However, the panellists eval-
uated other parameters with moderate and strong
similarity to aronia juice. Additionally, overall impres-
sion of matching the placebo formulations with aronia
juice was evaluated as high for each of the tested pla-
cebos. The colour of the final placebo was graded at
level 5- very strong similarity to aronia juice. The
presence of “Blueberry” flavour partly contributed to
this, since it contained artificial colour (3% of its con-
tent), unlike the “Aronia” flavour used for preparation
of the other two placebo formulations.
Furthermore, we showed that this placebo was well
tolerated in 20 apparently healthy human volunteers
without any reported side effects. Besides the evalu-
ation of blood lipids and glucose, activities of liver



































































































































4 N. KARDUM ET AL.
aminotrasnferase (AST) and gamma-glutamyltransfer-
ase (GGT), as indicators of liver function were also
monitored. Additionally, the effects on kidney func-
tion were examined by measuring concentrations of
creatinine, urea and uric acid in blood samples
obtained at the baseline and at the end of the con-
sumption period. Finally, we demonstrated that the
placebo beverage is inert with respect to possible
effects on platelet reactivity.
Taking into account obtained results and scarce lit-
erature data, we consider this study of great import-
ance for the future research of potential beneficial
effects of aronia juice polyphenols in humans, aiming











































































































Table 2. Characteristics of subjects at baseline and after 4 weeks of regular placebo
consumption.
Baseline 4 weeks P value
Gender (M/F) 10/10
Age (years)a 38.6 ± 6.7
Body mass index (kg/m2)a 27.7 ± 2.7 27.6 ± 2.6 0.379
Waist circumference (cm)a 94.3 ± 9.1 94.5 ± 9.1 0.812
SBP (mmHg)a 128.4 ± 13.6 125.6 ± 15.3 0.122
DBP (mmHg)a 79.9 ± 11.5 77.2 ± 12.9 0.107
Glucose (mmol/L)b 5.07 (4.77–5.36) 5.00 (4.70–5.44) 0.212
Triglycerides (mmol/L)b 1.36 (0.94–1.67) 1.24 (0.76–2.06) 0.332
Total cholesterol (mmol/L)a 5.61 ± 1.09 5.43 ± 0.78 0.200
LDL cholesterol (mmol/L)a 3.92 ± 1.11 3.70 ± 0.77 0.132
HDL cholesterol (mmol/L)a 1.51 ± 0.47 1.56 ± 0.52 0.608
ALT (U/L)a 31.3 ± 10.9 31.0 ± 12.9 0.867
AST (U/L)b 21.7 (18.5–25.8) 21.4 (18.2–25.2) 0.478
GGT (U/L)b 18.7 (11.2–31.5) 15.4 (10.0–28.6) 0.247
Creatinine (lmol/L) 71.10 (58.88–76.05) 63.30 (53.48–74.80) 0.211
Urea (mmol/L) 3.44 ± 1.11 3.23 ± 0.93 0.365
Uric acid (lmol/L) 279.24 ± 71.58 261.36 ± 84.64 0.323
aData are presented as mean ± SD.
bData are presented as median and 25th–75th percentile.
Figure 1. Platelet activation at baseline and after 4 weeks of regular placebo consumption; the percentage of P-selectin-positive
plateletes at basal state (a) and after stimulation with adenosine diphosphate – ADP (b); The percentage of GPIIb-IIIa-positive plate-
lets at basal state (c) and after stimulation with adenosine diphosphate – ADP (d).
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Although some in vitro studies have demonstrated a
positive impact of aronia products on platelet aggrega-
tion and their adhesion to collagen and fibrinogen
(Ryszawa et al. 2006; Olas et al. 2008; Malinowska
et al. 2013; Sikora et al. 2014), these effects have not
been confirmed in placebo-controlled trials so far.
Further, there is a limited number of human studies
investigating the effects of Aronia products on cardio-
vascular health using the pure aronia juice (Simeonov
et al. 2002; Skoczy~nska et al. 2007; Poreba et al. 2009;
Kardum et al. 2015). Most often these studies are
uncontrolled, or even if they do report use of appro-
priate placebo, they lack the detail description of the
control drink’ composition (Handeland et al. 2014).
What distinguishes our work is the inclusion of the
recipe for placebo – given in details – along with the
description of its sensory evaluation in terms of taste,
small and colour testing. The main challenge of our
study was to develop a placebo which could suffi-
ciently match the astringent taste of aronia juice. This
is not surprising, considering that aronia juice, as a
complex mixture of flavour and pigmenting com-
pounds, is characteristic for its astringency, which is
hard to mimic since it is caused by the bioactive com-
pounds (Kulling & Rawel 2008). Like ours, placebo
drink applied in a study evaluating effects of aronia
juice on urinary tract, contained blueberry aroma, in
addition to the grape one. However, since sensory
evaluation of this drink is lacking we could not con-
clude whether it matched the astringency of aronia
juice better or at the same level as the placebo
described in our study (Handeland et al. 2014).
Similar difficulties in developing liquid placebo have
been reported for other natural and herbal products.
Clinical study, aimed to develop and evaluate a pla-
cebo for a complex liquid herbal supplement, failed to
achieve the specific mint flavour and smell of the
product (Yoon et al. 2012). Comparing with the phar-
maceuticals, herbal materials are a much serious chal-
lenge for developing credible placebos. However, even
for pharmaceuticals placebos can differ from active
forms – especially when active forms affect smell or
taste (e.g. antibiotics, antidepressants and diuretics)
(Doty & Bromley 2004). The challenges of demon-
strating the activity of a single compound in the con-
text of complex foods, researchers often revert to the
reductionist approach and use pure compounds or
crude extracts rather than whole foods. When using
extracts, placebos are much more easily formulated











































































































Figure 2. Platelet aggregation at baseline and after 4 weeks of regular placebo consumption; The percentage of platelet-monocyte
(PMA) aggregats at basal state (a) and after stimulation with adenosine diphosphate – ADP (b); The percentage of platelet-
neutrophil aggregates at basal state (c) and after stimulation with adenosine diphosphate – ADP (d).
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from a simple blend of inorganic salts or other inert
substances (Dube et al. 2007; Chang et al. 2010). This
approach can lead to false conclusions; it has been
demonstrated that some components express their
effects only when they are delivered along with and
are able to interact with other food components
(Jacobs & Tapsell 2007). The results of a pilot study
showed no significant effect on liver and kidney func-
tion, indicating that placebo was well tolerated and
caused no observed side effects. This was in accord-
ance with our expectations, since the placebo was
prepared from nutrients allowed for human consump-
tion and commonly used in the food industry.
Additionally, artificial colours and flavours, present in
placebo formulation, were applied in amounts permit-
ted by the EU legislation for liquid food supplements.
The main purpose of developing the placebo was
its use in a study that aimed to assess the impact of
aronia juice polyphenols on platelet function; thus, we
also tested for possible effects of the placebo on plate-
lets. Cardiovascular disease (CVD), as one of the most
frequent chronic diseases, is, among other factors,
influenced by activated platelets. Altered platelet func-
tion, manifested by an increase in circulating platelets,
which express more adhesion molecules on cell sur-
face, has been found in subjects with hypercholesterol-
aemia, hypertension, diabetes mellitus and metabolic
syndrome (Lip 2003; Angiolillo et al. 2007; Santilli
et al. 2012; Br€oijersen et al. 1998a). Furthermore,
enhanced platelet activity was also detected after con-
sumption of meals containing fat, as well as after
treatment with high glucose levels in vitro (Br€oijersen
et al. 1998b; Sudic et al. 2006). Here, we showed that
placebo consumption caused no changes in platelet
activity, including platelet activation and aggregation
with other blood cells. Our study also showed no
effects of placebo consumption on the levels of blood
glucose and lipids, which is noteworthy because glu-
cose and lipid status affect not only CVD develop-
ment, but platelet function as well.
Conclusions
Despite obvious challenges, we developed a polyphe-
nol-free placebo formulation that was well matched to
Aronia juice in terms of taste, smell and appearance.
The placebo was well tolerated and its consumption
had no side effects in humans. Furthermore, we dem-
onstrated that consumption of the placebo had no
effects on platelet activation, platelet aggregation with
other blood cells, and biochemical parameters related
to the platelet functionality. We conclude that this
well characterised beverage can be used as a placebo
to facilitate controlled human intervention studies
assessing the effects of aronia juice polyphenols on
platelet function and on other biomarkers of health
and risk factors for diseases.
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